Effect of Statins Versus Untreated Dyslipidemia on Serum Uric Acid Levels in Patients with Coronary Heart Disease: A Subgroup Analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

American Journal of Kidney Diseases

Volumn 43, Issue 4, 2004, Pages 589-599

  Athyros, Vasilios G ^a   Elisaf, Moses ^a   Papageorgiou, Athanasios A ^a   Symeonidis, Athanasios N ^a   Pehlivanidis, Anthimos N ^a   Bouloukos, Vasilios I ^a   Milionis, Haralambos J ^a   Mikhailidis, Dimitri P ^a  

^a NONE

Author keywords

Coronary heart disease (CHD); Dyslipidemia; Serum uric acid (SUA); Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FLUINDOSTATIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LOSARTAN; NITRATE; PRAVASTATIN; URIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; URIC ACID BLOOD LEVEL;

EID: 1542268611     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.12.023     Document Type: Article

References (45)

1. Gertler MM, Garn SM, Levine SA: Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med 34:1421-1431, 1951
2. Alderman MH, Cohen H, Madhavan S, et al: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144-150, 1999
3. Ward HJ: Uric acid as an independent risk factor in the treatment of hypertension. Lancet 352:670-671, 1998
4. Yano K, Reed DM, McGee DL: Ten-year incidence of coronary heart disease in the Honolulu Heart Program: Relationship to biologic and lifestyle characteristics. Am J Epidemiol 119:653-666, 1984
5. Fessel WJ: High uric acid as an indicator of cardiovascular disease: Independence from obesity. Am J Med 68:401-404, 1980
6. Culleton BF, Larson MG, Kannel WB, et al: Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 131:7-13, 1999
7. Wannamethee SG, Shaper AG, Whincup PH: Serum urate and the risk of major coronary heart disease events. Heart 78:147-153, 1997
8. Freedman DS, Williamson DF, Gunter EW, et al: Relation of serum uric acid to mortality and ischemic heart disease: The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637-644, 1995
9. Levine W, Dyer AR, Shekelle RB, et al: Serum uric acid and 11.5-year mortality of middle-aged women: Findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 42:257-267, 1989
10. Bickel C, Rupprecht HJ, Blankenberg S, et al: Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89:12-17, 2002
11. Franse LV, Pahor M, Di Bari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18:1149-1154, 2000
12. Verdecchia P, Schillaci G, Reboldi G, et al: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36:1072-1078, 2000
13. Wang JG, Staessen JA, Fagard RH, et al: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 37:1069-1074, 2001
14. Longo-Mbenza B, Luila EL, Mbete P, et al: Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans? Int J Cardiol 71:17-22, 1999
15. Lehto S, Niskanen L, Ronnemaa T, et al: Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 29:635-639, 1998
16. Elisaf M: Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18:269-276, 2002
17. Athyros VG, Papageorgiou AA, Mercouris BR, et al: Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary Coronary Heart Disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220-228, 2002
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
19. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
20. Elisaf M, Tsichodimos V, Bairaktari E, Siamopoulos KC: Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 34:60-63, 1999
21. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283:2404-2410, 2000
22. Newland H: Hyperuricemia in coronary, cerebral and peripheral arterial disease: An explanation. Med Hypotheses 1:152-155, 1975
23. Emmerson BT: Atherosclerosis and urate metabolism. Aust NZ J Med 9:451-454, 1979
24. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ: Release of platelet constituents by monosodium urate crystals. J Clin Invest 60:999-1007, 1977
25. Vasquez-Vivar J, Santos AM, Junqueira VB, Augusto O: Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J 314:869-876, 1996
26. Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ: Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart 78:39-43, 1997
27. Leyva F, Anker S, Swan JW, et al: Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 18:858-865, 1997
28. Paolisso G, Barbagallo M, Petrella G, et al: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150:121-127, 2000
29. Athyros VG, Papageorgiou AA, Symeonidis AN, et al: Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. A subgroup analysis of the GREek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Angiology 54: 679-690, 2003
30. Gin H, Rigalleau V, Aparicio M: Lipids, protein intake, and diabetic nephropathy. Diabetes Metab 26:S45-S53, 2000 (suppl. 4)
31. Mänttäri M, Tiula E, Alikoski T, et al: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26:670-675, 1995
32. Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 53:493-502, 2002
33. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 26:152-161, 1995
34. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H: Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 98:1291-1296, 1998
35. O'Donnell MP, Kasiske BL, Kim Y, et al: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 22:83-89, 1993
36. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP: Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 19:615-617, 2003
37. Steinmetz A, Schwartz T, Hehnke U, et al: Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 27:563-570, 1996
38. Tsalamandris C, Panagiotopoulos S, Sinha A, et al: Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk 1:231-239, 1994
39. Gardner SF, Schneider EF, Granberry MC, et al: Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 16: 419-423, 1996
40. Locsey L, Asztalos L, Kincses Z, et al: Fluvastatin treatment of hyperlipidaemia in patients with renal transplants. Int Urol Nephrol 29:95-106, 1997
41. Sinzinger H, Kritz H, Furberg CD: Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. Med Sci Monit 9:88-92, 2003
42. Kakafika A, Liamis G, Elisaf M, et al: Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 17:230-231, 2001
43. Marais AD, Firth JC, Bateman ME, et al: Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:1527-1531, 1997
44. Giral P, Bruckert E, Jacob N, et al: Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154:421-427, 2001
45. Youssef F, Seifalian AM, Jagroop IA, et al: The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 23:358-364, 2002